Skip to content
Eli Lilly
-
Eli Lilly expands partnership with Nimbus Therapeutics to develop oral weight loss drug
Nimbus will leverage its specialized expertise in computational chemistry and structure-based drug design to discover a small molecule drug candidate.
-
Eli Lilly’s Jaypirca reduces the risk of disease progression by 80% in first-line CLL trials
The study compared the drug against bendamustine plus rituximab (BR) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who had not received prior treatment and did not have 17p deletions.
-
Eli Lilly opens a USD6B Orforglipron facility in Alabama
The Alabama site is part of Lilly’s USD 27 billion U.S. onshoring initiative, aimed at reinforcing domestic pharmaceutical manufacturing.